RUNNING TITLE: Nuclear survivin expression in ESCC
INTRODUCTION
Despite advances in surgical technique and perioperative management that have improved survival to some extent, esophageal squamous cell carcinoma (ESCC) remains a disease with a poor prognosis. The overall 5-year survival rate generally remains less than 50%, even with the use of multimodality therapy. [1] [2] [3] Recently, there has been a better understanding of the molecular basis of esophageal carcinogenesis, and prognostically important biologic markers have been identified. Survivin is a member of the inhibitors of apoptosis protein family. Survivin participates in the complex network regulating programmed cell death and cell division. [4] [5] [6] Survivin protein is commonly detected in fetal tissues, but not in normal adult tissues. Survivin is overexpressed in several human cancers, which suggests that the reactivation of the survivin gene contributes to carcinogenesis. 4 Overexpression of survivin has been associated with parameters of aggressiveness and poor prognosis in several solid tumors; 4,7-9 however, conflicting data have also been reported. 10 The aim of the present study was to investigate the association of survivin expression with surgical data, response to chemotherapy and prognosis in a large group of primary ESCC patients who underwent surgical resection. Immunohistochemical studies were performed on 122 surgical specimens of ESCC. Clinical and histopathologic factors were obtained from a retrospective review of patient records.
MATERIALS AND METHODS
Patients and esophageal specimens. We examined all complete ESCC surgical specimens resected from 1989 to 1999. We included only the patients who had no evidence of metastasis to other organs and who did not receive prior anticancer treatment. Cases of in-hospital death were excluded. Surgical specimens from 122 patients who had undergone radical esophagectomy at the Department of Surgical Oncology at Hokkaido University, Hokkaido Gastroenterology Hospital, and Teine Keijinkai Hospital were included in the current study. Data was collected from the patients' clinical records. For each patient, one section from the deepest point of tumor invasion was selected for evaluation. The specimens were examined histologically after staining with hematoxylin and eosin, and the clinicopathologic stage was determined according to the TNM classification system of the International Union Against Cancer. 11 The 122 patients included in the study consisted of 105 men and 17 women. The median patient age was 62.3 years (range, 38 to 82 years). A relatively large number of patients had early stage disease (78 patients, 64%). Sixty-one patients (50%) had lymph node metastases, and 19 patients (16%) had distant nodal metastases. The study population had the following performance status (PS): PS0, 107 patients; PS1, 14 patients; and PS2, 1 patient. The median follow-up period was 29 months.
All specimens were fixed in 10% formalin and embedded in paraffin wax. One of the deepest sections from each tumor was selected for evaluation. Serial 4 micrometer-thick sections were examined by immunohistochemistry.
Immunohistochemistry. Each slide was deparaffinized in xylene, rehydrated and washed in PBS for 15 min. Antigen retrieval was achieved by treating the slides in a pressure cooker containing 1.5 l of boiling water. Slides were treated in the pressure cooker for 7 minutes in 10mM citrate buffer at pH 6.0. Endogenous peroxidase activity was blocked with 0.3% H 2 O 2 in methanol for 30 min. Non-specific binding was blocked by incubating the slides with 10% normal goat serum (Histofine SAB-PO kit; Nichirei, Tokyo, Japan) for 30 min. The slides were incubated overnight at 4 ℃ with the primary antibody. Polyclonal rabbit anti-human survivin antibody (diluted 1:20; Alpha Diagnostic International, San Antonio, TX, USA) was used under previously described conditions. 9 After washing, sections were treated with biotinylated secondary antibody (Histofine Simple Stain MAX-PO (MULTI), Nichirei, Tokyo, Japan) for 30 min. Then, sections were incubated with peroxidase-conjugated streptavidin for 30 min.
Visualization of the immunoreaction was conducted with 3, 3'-diaminobenzidine (DAB and DAB H 2 O 2 ; Ventana DAB Universal Kit; Ventana-Bio Tek Solutions, Tokyo, Japan) for 5 min. Finally, sections were counterstained with haematoxylin. As a negative control, nonimmune purified rabbit serum was used for the primary antibody.
Assessment of immunoreactivity.
Survivin immunoreactivity was observed in the nucleus and cytoplasm of cancer cells. Tumor cells were considered survivin-positive if the immunoreactivity was observed nucleus by the previous study. 12 To quantitate survivin expression in the various samples, a scoring method was applied. 8, 13 The mean percentage of positive tumor cells was determined from at least 1000 tumor cells that were counted systematically at ×400 magnification (Olympus Optical Co, Ltd, Tokyo, Japan) in 5 visual fields. The percentage of positive tumor cells was assigned to one of the following categories: 0, <5%; 1, 5-25%; 2, 26-50%; 3, 51-75%; and 4, >75%. The intensity of nuclear survivin immunostaining was scored as follows: (a) weak, 1+; (b) moderate, 2+; and (C) intense, 3+. For tumors with heterogeneous staining, the predominant pattern was taken into account for scoring. The percentage of positive tumor cells and the staining intensity were multiplied to produce a weighted score for each case. Cases with a weighted survivin score <1 were considered to be negative. The current study was performed in a retrospective manner. All specimens were evaluated 
RESULTS
We performed immunohistochemical analysis on 122 ESCC specimens. Survivin immunoreactivity was observed in the nucleus and cytoplasm of cancer cells, as seen in a previous study. 12, 13 Fifty-four specimens (44.3%) were immunoreactive for nuclear survivin in less than 5% of cells; 20 specimens (16.4%) were immunoreactive in 5-25% of cells; 22 specimens (18.0%) were immunoreactive in 26-50% of cells; 18 specimens (14.7%) were immunoreactive in 51-75% of cells; 8 specimens (6.6%) were immunoreactive in more than 75% of cells. According to the criteria of the current study, 68 specimens (55.7%) were positive for survivin ( Fig. 1 ). Table   1 . The average age of survivin-positive patients was 62.9 years (range, 47-82 years), and the average age of survivin-negative patients was 61.7 (range, 38-78 years). Of the 68 patients (55.7%) who were positive for survivin, 62 (91.2%) were men and 6 (8.8%) 6 were women. The over-expression of survivin was not related to gender (P=0.0674) or age (P=0.1684). Survivin immunoreactivity had a statistically significant relationship to the p-N classification (P=0.0472) of clinicopathological features, as determined by the chi-square test (Table 1) Multivariate analyses indicated that T classification (P=0.0090) and N classification (P=0.0004) were independent prognostic factors. Survivin positivity was not an independent factor (P=0.2373) ( Table 2) .
Associations between survivin over-expression and clinical factors are shown in

DISCUSSION
Recently, several reports have suggested that survivin is over expressed in many types of human tumors. 7, [14] [15] [16] [17] [18] [19] [20] Overexpression of survivin may lead to promote cell survival. Because survivin can directly inhibit the activities of caspase-3 and caspase-7, one role of survivin may be the prevention of apoptosis. [21] [22] [23] Thus, overexpression of survivin may increase the malignant potential of a tumor. Immunohistochemical expression of the first-characterized anti-apoptotic gene, Bcl-2, which regulates an apoptotic pathway different from that of survivin, has been reported in ESCC. 24, 25 But there were few previous reports about nuclear survivin expression in cancer cells.
Therefore, we performed an immunohistochemical analysis of survivin in 122 ESCC specimens. We believe that this manuscript is the first report about a large group analysis of nuclear survivin expression to clinicopathological status in ESCC.
Our analysis provides suggestions for the biological function of survivin in ESCC.
We found survivin expression in both the nucleus and cytoplasm of ESCC specimens. In normal squamous cell epithelium of the esophagus, survivin expression was occasionally recognized weakly; this expression was mainly localized in the cytoplasm of the basal layer. But, in high-grade dysplasia and aggressive tumor tissues, survivin expression was often recognized in the nucleus as well as the cytoplasm. And nuclear survivin expression found more intensively at invasive tumor cells. These differences in staining may be related to another function of survivin, cell proliferation.
Previous studies have suggested that nuclear survivin expression is more important than cytoplasmic expression in clinicopathological studies. 12, 21 So, we adopted scoring methods to quantify nuclear survivin immunoreactivity. In this study, the ratio of nuclear survivin immunopositivity was associated with overall survival rate, and the overexpression of survivin was significantly associated with a poor prognosis (P=0.0189). We think that the poor prognosis was caused by a significant association between nuclear survivin expression and lymph node metastasis (P=0.0472) ( Table 1) .
Interestingly, the percentage of patients who overexpressed survivin tended to increase with pathological T-classification and stage progression. These data suggest that survivin overexpression is implicated in the resistance to apoptotic stimuli, so that survivin overexpression may reflect the tumor progression and malignancy in ESCC.
Survivin may be targeted during cancer therapy because of its selective expression in malignant tissue.
We conclude that overexpression of survivin was not a independent prognostic factor, but it may be effective to predict poor prognosis in patients with ESCC.
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